Advances in Therapy · 2023 · 10 citations · 18 references
PharmacyNeuroscienceGene TherapyNeurogeneticsPalliative MedicineLong-term Follow-upNeurologic PrognosticationTreatment Pathway ModelingAromatic L-amino Acid DecarboxylaseGene-targeted TherapyLifetime HorizonLong-term Disability BenefitsLong-term Neurologic OutcomesMotor Milestone AcquisitionMotor Symptom ProgressionNeurodevelopmental Sequelae Of Amino Acid Disorders
INTRODUCTION: Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare disease with symptoms including movement disorders, developmental delays, and autonomic symptoms starting from birth; further, patients with AADC deficiency are at a high risk of death in the first decade of life. Limited information on the impact of treatment with gene therapy on patients' disease trajectories and survival, quality-of-life, and resource usage benefits are available. METHOD: A cohort-based model with a lifetime horizon has been developed, based on motor milestones, to estimate the long-term benefits for patients after treatment with eladocagene exuparvovec compared to best supportive care (BSC). The model takes a National Health Service (NHS) perspective using a UK setting. The model comprises two parts: the developmental phase, in which patients with initially no motor function can progress to other motor milestone states, and a long-term projection phase. Efficacy for eladocagene exuparvovec is derived from clinical trial data with a duration up to 120 months. As the incidence of AADC deficiency is low, data for key model inputs is lacking; therefore estimates of survival by motor milestone were based on proxy diseases. A disease-specific utility study provided quality of life inputs and a burden of illness study informed inputs for disease management. RESULTS: The model indicates survival (25.25 undiscounted life years gained) and quality-of-life benefits (20.21 undiscounted quality-adjusted life years [QALYs] gained) for patients treated with eladocagene exuparvovec compared to BSC. Resource usage costs are greater for patients treated with eladocagene exuparvovec, mainly due to the increased life expectancy during which patients accrue additional healthcare resource usage. Scenario analyses indicate robust results. CONCLUSION: This study assessed long-term outcomes for patients with AADC deficiency. Patients treated with eladocagene exuparvovec were found to have improved survival and quality of life benefits compared to patients treated with BSC.
18
Results from a phase I safety trial of <i>hAADC</i> gene therapy for Parkinson disease
Jamie L. Eberling, William J. Jagust, Chadwick W. Christine et al. · Neurology · 2008 · 367 citations
Medicine, Neurology, Neuroscience +17
A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease
Shin‐ichi Muramatsu, Kenichi Fujimoto, Seiya Kato et al. · Molecular Therapy · 2010 · 338 citations · Full text
Medicine, Neurology, Neuroscience +17
Eve Blair, Katherine Langdon, Sarah McIntyre et al. · BMC Neurology · 2019 · 189 citations · Full text
Aromatic L‐amino acid decarboxylase deficiency
Robert Surtees, Charles H. Rodeck, Peter T. Clayton · Neurology · 1992 · 173 citations